Vogl, NY
RxPonder Changes the Field for Premenopausal Breast Cancer Patients With Involved Nodes
Attention must be paid to this large study that showed a substantial 5-year benefit from adding chemotherapy to the ...
FEBRUARY 25, 2021
RxPonder Results for Postmenopausal Women: Skip Chemo With RS <26 and 1 to 3 Positive Nodes
RxPonder is not a noninferiority study showing that we lose very little by skipping chemotherapy for postmenopausal ...
FEBRUARY 25, 2021
Vogl, NY: Oral Paclitaxel—Handle with Care and Skepticism
At least 4 reasons exist for clinicians and federal agencies to question the results presented to date.
MAY 18, 2020
A Viper Bites Med Literature Again: Guarantee-Time Bias
The February 10, 2017, issue of the Journal of Clinical Oncology (JCO) included a matched propensity score ...
JULY 5, 2017
Vogl, NY: Adjuvant OFS for Resected Breast Cancer Revisited
After the results of the Eastern Cooperative Oncology Group (ECOG) 5188 study (Intergroup 0101) were published by ...
APRIL 29, 2017
Value of Extended Adjuvant AI Therapy Is Still Unclear
At SABCS 2016, investigators reported 3 new studies on extended adjuvant aromatase inhibitors (AIs)—a large ...
FEBRUARY 13, 2017
